These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 25307430

  • 1. Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients.
    Takenaka K, Kato M, Yamauti K, Hayashi K.
    J Stroke Cerebrovasc Dis; 2014; 23(10):2748-2752. PubMed ID: 25307430
    [Abstract] [Full Text] [Related]

  • 2. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S, Deguchi K, Morimoto N, Kurata T, Yamashita T, Ikeda Y, Narai H, Manabe Y, Takao Y, Kawada S, Kashihara K, Takehisa Y, Inoue S, Kiriyama H, Abe K.
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
    Tanahashi N, Yamaguchi T, Awano H, Matsuda H.
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1302-1310. PubMed ID: 29373227
    [Abstract] [Full Text] [Related]

  • 5. Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator.
    Lee XR, Xiang GL.
    Clin Neurol Neurosurg; 2018 Apr; 167():157-161. PubMed ID: 29501045
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
    Tsuruoka A, Atsumi C, Mizukami H, Imai T, Hagiwara Y, Hasegawa Y.
    J Stroke Cerebrovasc Dis; 2014 Apr; 23(10):2894-2899. PubMed ID: 25282183
    [Abstract] [Full Text] [Related]

  • 8. [Thrombolysis by intravenous tissue plasminogen activator (t-PA)--current status and future direction].
    Tanahashi N.
    Brain Nerve; 2009 Jan; 61(1):41-52. PubMed ID: 19177806
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger.
    Baba H, Sugimori H, Nanishi E, Nagata H, Lee S, Kuwashiro T, Hashizume M.
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):903.e5-8. PubMed ID: 21421331
    [Abstract] [Full Text] [Related]

  • 12. Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study.
    Kimura K, Aoki J, Sakamoto Y, Kobayashi K, Sakai K, Inoue T, Iguchi Y, Shibazaki K.
    J Neurol Sci; 2012 Feb 15; 313(1-2):132-6. PubMed ID: 21967833
    [Abstract] [Full Text] [Related]

  • 13. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial.
    Pancioli AM, Adeoye O, Schmit PA, Khoury J, Levine SR, Tomsick TA, Sucharew H, Brooks CE, Crocco TJ, Gutmann L, Hemmen TM, Kasner SE, Kleindorfer D, Knight WA, Martini S, McKinney JS, Meurer WJ, Meyer BC, Schneider A, Scott PA, Starkman S, Warach S, Broderick JP, CLEAR-ER Investigators.
    Stroke; 2013 Sep 15; 44(9):2381-7. PubMed ID: 23887841
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M, Matthis C, Eggers J.
    J Stroke Cerebrovasc Dis; 2014 Jan 15; 23(1):7-11. PubMed ID: 22578915
    [Abstract] [Full Text] [Related]

  • 16. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain.
    Zhang W, Sato K, Hayashi T, Omori N, Nagano I, Kato S, Horiuchi S, Abe K.
    Neurol Res; 2004 Apr 15; 26(3):342-8. PubMed ID: 15142331
    [Abstract] [Full Text] [Related]

  • 17. Outcome of intravenous recombinant tissue plasminogen activator for acute ischemic stroke in patients aged over 80 years.
    Mione G, Ducrocq X, Thilly N, Lacour JC, Vespignani H, Richard S.
    Geriatr Gerontol Int; 2016 Jul 15; 16(7):843-9. PubMed ID: 26245693
    [Abstract] [Full Text] [Related]

  • 18. Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke?
    Shaltoni HM, Albright KC, Gonzales NR, Weir RU, Khaja AM, Sugg RM, Campbell MS, Cacayorin ED, Grotta JC, Noser EA.
    Stroke; 2007 Jan 15; 38(1):80-4. PubMed ID: 17122433
    [Abstract] [Full Text] [Related]

  • 19. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S.
    JAMA; 1999 Dec 01; 282(21):2019-26. PubMed ID: 10591384
    [Abstract] [Full Text] [Related]

  • 20. Cerebral Microbleeds are an Independent Predictor of Hemorrhagic Transformation Following Intravenous Alteplase Administration in Acute Ischemic Stroke.
    Nagaraja N, Tasneem N, Shaban A, Dandapat S, Ahmed U, Policeni B, Olalde H, Shim H, Samaniego EA, Pieper C, Ortega-Gutierrez S, Leira EC, Adams HP.
    J Stroke Cerebrovasc Dis; 2018 May 01; 27(5):1403-1411. PubMed ID: 29398533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.